Forty dogs from the periphery of the city of Rio de Janeiro were studied. All dogs where diagnosed as positive for leishmaniasis either parasitologically and/or serologically. Among them, 19 came from areas where only Visceral Leishmaniasis (VL) occurs (Realengo, Bangu, Senador Camará). Clinical signs of the disease were seen in 36.8% of the cases, including emaciation - 100%, lymphadenopathy and depilation - 85.7%. The other 21 dogs came from an area (Campo Grande) where both diseases (VL, and American Cutaneous Leishmaniasis - ACL) occur. Clinical signs of the disease, mainly cutaneous or mucocutaneous ulcers were seen in 76.2% of the cases. Leishmania parasites were found in 39 cases: 22% in viscera, 42.5% in viscera and normal skin and 35% in cutaneous or mucocutaneous ulcers. All the Leishmania stocks isolated from dogs which came from Realengo, Bangu, Senador Camará (VL area), and from Campo Grande (VL + ACL area) were characterized as L. donovani (except in one case) according to their schizodeme, zymodeme and serodeme. The only stock characterized as L. b. braziliensis, was isolated from the lymph node of a dog from Campo Grande with visceral disease and without skin lesions. Antimony therapy attempted in eight Leishmania donovani positive dogs was unsuccessful.

INTRODUÇÃOA leishmaniose visceral (LV) canina, no Brasil, coexiste com a doença humana em todos os focos conhecidos sendo, porém, mais prevalente e, regra geral, precedendo à ocorrên-cia de doença humana 3 . Os cães infectados pela Leishmania donovani chagasi, à semelhança do calazar canino do Mediterrâneo, apresentam um bem conhecido espectro de características clínicas que podem variar de aparente estado sadio ao severo estágio final. Classicamente, na LV canina, tanto natural como experimentalmente induzida, se admite um período de incubação e prepatente de 3 a 6 meses até vários anos. Esta, invariavelmente, evolui para os estados latente ou patente que, por sua vez, em períodos variáveis de semanas, meses ou anos, podem evoluir para a forma aguda, subaguda, crô-nica ou regressiva 3,9,21 . De modo geral, o quadro clínico se assemelha à doença humana, com febre irregular de longo curso, palidez de mucosas e um emagrecimento progressivo, até o estado de caquexia intensa, na fase terminal. A hiperRecebido para publicação em 29/07/85

Foi realizado um inquérito entomológico no período de agosto a dezembor de 1977 na área de procedência de caso autóctone de leishmaniose visceral, encosta do Rio da Prata, bairro de Bangu, Rio de Janeiro. Utilizando-se capturadores manuais foram investigados os peri-domicílios de 13 das 27 habitações da área, tendo-se selecionado quatro locais de capturas que haviam demonstrado serem de maior produtividade. Em 22 capturas (73,3 horas - capturador), coletou-se 1.585 flebotomíneos, sendo 828 (52,2%) Lutzomyia intermediata, 684 (43,1%) Lutzomyia longipalpis, 57 (3,6%) Lutzomyia migonei, 5 (0,3%) Lutzomya cortelezzii e Lutzomyia fischeri, 3 (0,2%) Lutzomyia micropyga, 1(0,1%) LUtzomyia firmatoi e 2 (0,2%) Brumptomyia sp. L. longipalpis predominou nos locais de captura acima de 100 metros de altitude, tanto em abrigos de animais do tipo galinheiro como chiqueiro. A maioria deles foi capturada no horário entre 18 e 21 horas mas eventualmente foram também capturados entre 15 e 17 horas. L. intermedia predominou abaixo de 100 metros e em chiqueiro, sendo encontrados em galinheiro menos freqüentemente que L. longipalpis. Os autores ressaltam a necessidade de adoção de medidas de controle na localidade, dado o risco potencial de transmissão de leishmaniose visceral em área próxima a grande concentração urbana.

In previous studies, we identified promising anti-Trypanosoma cruzi cruzain inhibitors based on thiazolylhydrazones. To optimize this series, a number of medicinal chemistry directions were explored and new thiazolylhydrazones and thiosemicarbazones were thus synthesized. Potent cruzain inhibitors were identified, such as thiazolylhydrazones 3b and 3j, which exhibited IC(50) of 200-400nM. Furthermore, molecular docking studies showed concordance with experimentally derived structure-activity relationships (SAR) data. In the course of this work, lead compounds exhibiting in vitro activity against both the epimastigote and trypomastigote forms of T. cruzi were identified and in vivo general toxicity analysis was subsequently performed. Novel SAR were documented, including the importance of the thiocarbonyl carbon attached to the thiazolyl ring and the direct comparison between thiosemicarbazones and thiazolylhydrazones.

In this study, we have the objective of evaluating the lymphoproliferative response and determining interferon (IFN)‐γ and interleukin (IL)‐10 cytokine production in the peripheral blood mononuclear cells (PBMC) of patients with American tegumentary leishmaniasis prior and post 12 months of chemotherapy treatment with meglumine antimoniate compared with the PBMC of noninfected donors. Lymphoproliferation, such as cytokine production, was evaluated through in vitro stimulus with the soluble antigenic fraction from Leishmania (Viannia) braziliensis promastigotes (1.25 µg/ml) and Concanavalin A (2.5 µg/ml). Patients showed a significant lymphoproliferative response prior and post treatment compared with the control group. Similar result, prior to chemotherapy treatment, was observed in IFN‐γ and IL‐10 production when patients were compared with the control group. After chemotherapy treatment, PBMC lymphoproliferative response of the patients revealed an increase, whereas patients have shown a decrease in IFN‐γ levels and an increase in IL‐10, although without statistical difference. These results may indicate that the patients produced a specific cellular response to the soluble antigenic fraction suggesting that besides Th1 and Th2 dichotomy, immunological regulation mechanisms with the participation of memory T cells and regulatory T cells could be present in the clinical evolution of these patients. This understanding will allow the study and identification of new L. (V.) braziliensis molecules potentially candidates to vaccines. J. Clin. Lab. Anal. 23:63–69, 2009. © 2009 Wiley‐Liss, Inc.